Unoperated Patients With Severe Aortic Stenosis  by Bach, David S. et al.
CORRESPONDENCE
Research
Correspondence Unoperated Patients With Severe Aortic Stenosis
To the Editor: Aortic valve replacement (AVR) is an accepted
standard for the treatment of aortic stenosis (AS) (1,2). Patients
with symptoms exhibit superior survival after AVR, making
symptomatic severe AS a well-accepted indication for AVR. In
asymptomatic patients, stress testing is now accepted to help
estimate risk and guide AVR (2). Advanced age and comorbidities
that increase operative risk may result in failure to intervene (3–5).
One large, multicenter European survey suggested that only 47%
of patients with AS underwent AVR, and that 32% of patients
with severe single-valve disease and class III or IV symptoms did
not undergo intervention (6). Reasons included patient age and
perception of surgical risk. No data are available for similar patients
in the U.S. This survey examines the reasons why adult patients in
the U.S. with severe AS did not undergo AVR.
The University of Michigan echocardiography database was
reviewed to identify adult patients with evidence of severe AS
documented during calendar year 2005. Severe AS was defined as
a mean gradient 40 mm Hg, calculated valve area 1.0 cm2, or
overall echocardiographic assessment of severe AS. Medical
records were reviewed to determine whether there were symptoms
referable to AS. If AVR was not performed, records were reviewed
to determine why. For patients who did not undergo AVR,
anticipated operative risk of AVR was calculated using the logistic
EuroScore (7) using clinical data at the time of echocardiography.
The study protocol was approved by the institutional review board.
During 2005, 159 patients had an echocardiogram interpreted
to show severe AS. Four patients were excluded, 1 because of
insufficient medical information and 3 because AS was felt not to
be severe based on other data. Of the remaining 155 patients, 80
(52%) underwent AVR and 75 (48%) did not. The 75 unoperated
patients included 31 women and 44 men; mean age 68.1  15.0
years (range 34 to 91 years). Left ventricular ejection fraction was
normal in 60 of 75 (80%) patients and abnormal in 15 (20%). In
patients with systolic dysfunction, mean ejection fraction was 31
15% (range 10% to 50%). Of 75 unoperated patients, 66 (88%) had
comorbidities and 49 (74%) had multiple comorbidities; 30 pa-
tients had undergone previous open-heart surgery. Symptoms of
AS were present in 53 (71%) of 75 patients. In descending order
were symptoms of heart failure in 29 patients, symptoms of heart
failure and angina in 12, syncope or presyncope in 7, and angina
alone in 5. Although there were more elderly symptomatic than
asymptomatic patients (28% vs. 18%80 years), mean age did not
differ between groups (68.0  15.5 years vs. 68.3  14.1 years).
The number of comorbidities in symptomatic and asymptomatic
patients was not significantly different (2.6  1.9 vs. 2.1  1.6,
p  0.28). Of 22 asymptomatic patients, exercise testing was
performed in only 1. Of 75 patients with unoperated severe AS, 69
(92%) were evaluated by a cardiologist and 32 (43%) by a
cardiothoracic surgeon.
For 75 unoperated patients, calculated operative risk was 9.6 
11.8%. Operative risk was significantly lower among asymptomatic
patients (5.1  4.2%, range 0.9% to 14.8%) than among symp-
tomatic patients (11.5  13.4%, range 0.9% to 52.2%, p  0.03).
Operative risk was 5% in 25 (47%) of 53 symptomatic patients
and 10% in 34 patients (64%), and was 20% in 11 patients
(21%) and 40% in 5 patients (9%). Among 30 symptomatic
patients for whom prohibitive operative risk was cited as the major
rationale against AVR, calculated operative risk was 5% in 11
(37%) and 10% in 17 (57%); only 6 (35%) of these 17 were
evaluated by a surgeon.
Reasons that AVR was not performed are shown (Table 1).
Among 22 asymptomatic patients, the most common reason was
asymptomatic status. One of these patients was documented to
have no significant physical activity, and one is a paraplegic.
Medical contraindications included cancer and past history of
stroke. Exercise testing was performed in only 2 of 11 patients in
whom symptoms were attributed to another etiology.
Follow-up was available at 8.7  7.7 (range 0 to 23.5) months
after the echocardiogram. Survival is shown (Fig. 1). Eighteen
patients died (average interval 4.3  4.8 months after the echo-
cardiogram, range 0 to 14.2 months). Only 1 death was in a patient
who was asymptomatic. One patient died of cancer; the remaining
17 died of complications related to AS.
In this survey, approximately half of patients with severe AS
underwent AVR; this ratio is similar to the EuroHeart survey
(6). Almost three-quarters of unoperated patients were symp-
tomatic. Although the absence of symptoms was the most
common reason that AVR was not performed in asymptomatic
patients, inactivity was documented in several cases, and pro-
vocative stress testing was rarely used. Among symptomatic
patients, comorbidities were felt to preclude AVR in over half.
Calculated operative risk was very high in some patients, but did
not appear prohibitive in many others. Operative risk was10% in
more than half of symptomatic patients in whom prohibitive risk
was cited as precluding AVR, and fewer than one-third of these
were referred to a surgeon. Lack of familiarity with current
operative risks may have led nonsurgeons to overestimate risk,
Reasons That Aortic Valve Replacement Was Not Performed
Table 1 Reasons That Aortic Valve Replacement Was Not Performed
Asymptomatic patients (n  22)
Asymptomatic status 16 (73%)
Medically contraindicated 3 (14%)
Patient declined intervention 2 (9%)
Aortic stenosis unrecognized 1 (5%)
Symptomatic patients (n  53)
Prohibitive comorbidities 30 (57%)
Symptoms felt due to another etiology 11 (21%)
Died before surgery
Presented in cardiogenic shock 2 (4%)
Planned elective surgery 2 (4%)
Subvalvular obstruction 3 (6%)
Aortic stenosis unrecognized 3 (6%)
Patient declined intervention 2 (4%)
Journal of the American College of Cardiology Vol. 50, No. 20, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
Published by Elsevier Inc.
potentially denying patients access to surgery that was feasible. The
prognosis for unoperated severe symptomatic AS was very poor,
reinforcing the role of intervention. Although testing is still
preliminary, less invasive delivery of devices for the treatment of
severe AS may find a role in patients with truly prohibitive
operative risk.
It could be attractive to assume that these data are unique to
a single institution. However, the surveyed institution has an
active program in the treatment of valvular heart disease. The
authors believe that these findings are likely reflective of general
practice.
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Letters to the Editor
Myocardial Late Enhancement in
Duchenne and Becker Individuals
in the Clinical Milieu
We read with interest the study by Silva et al. (1) of myocardial
delayed enhancement (MDE) in patients with muscular dystrophy.
This study focuses on 10 patients, 8 Duchenne muscular dystrophy
(DMD) and 2 Becker muscular dystrophy (BMD) individuals age
7 to 18 years, 2 having dilated cardiomyopathy (DCM). It raises
several issues.
The authors reported a significant correlation between MDE, as
a marker of myocardial fibrosis (MF), and low left ventricular
ejection fraction (EF) values.
Although only 2 patients had MF and abnormal echocardiog-
raphy, their EF values were not shown. Similarly, the correlation
between EF and MF in the 5 patients with MF and normal
echocardiography should be focused on, as a wide variability in EF
data (37.3% to 59.3%) was observed.
Correlation between contractile dysfunction and MF seems
ambiguous, as 56.2% of dysfunctional segments had MF, whereas
43.8% did not.
Lack of muscle biopsy renders the diagnosis of 4 patients
incomplete: Patients #2 and #3 diagnosed as DMD, carrying an
in-frame (Becker) deletion. Patients #5 and #6 (siblings) were
diagnosed as BMD, despite the absence of muscle biopsy data. In
these patients without cardiomyopathy, the differential diagnosis
with limb-girdle dystrophy should be considered.
Seven patients had no deletions of the dystrophin gene. Sur-
prisingly, in these patients, screening for duplications or splicing
mutations was not performed. Indeed, Patients #1, #5, and #10
(without MF) could have early cardiac involvement undetectable
by cardiac magnetic resonance and develop severe DCM (2).
Finally, even the youngest patients (Patients #7 and #8) with MF
had no screening for mutations.
Regarding the early detection of heart involvement by cardiac
magnetic resonance in children, the authors did not cite ultrasound
tissue characterization analysis (3) that reveals early occult cardiac
involvement in all affected individuals.
Figure 1 Survival of Patients With Unoperated AS
Kaplan-Meier survival for patients with unoperated severe aortic stenosis (AS).
Survival estimates  1 standard error; log-rank difference in survival p  0.01.
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